Uptake and metabolic effects of 3-iodothyronamine in hepatocytes

Journal of Endocrinology

Volumn 221, Issue 1, 2014, Pages 101-110

  Ghelardoni, Sandra ^a   Chiellini, Grazia ^a   Frascarelli, Sabina ^a   Saba, Alessandro ^a   Zucchi, Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Glucose production; Hepatocytes; Metabolism; Thyronamines

Indexed keywords

3 IODOTHYRONAMINE; DIIODOTHYRONINE; FATTY ACID; GLUCOSE; IPRONIAZID; KETONE BODY; PYRUVIC ACID; THYRONINE DERIVATIVE; THYROXINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CATABOLISM; CELL METABOLISM; CELL STRAIN HEPG2; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EXPOSURE; DRUG UPTAKE; EXPERIMENTAL MODEL; GLUCONEOGENESIS; HUMAN; HUMAN CELL; KETOGENESIS; LIVER CELL; LIVER PERFUSION; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT; STEADY STATE;

GLUCOSE PRODUCTION; HEPATOCYTES; METABOLISM; THYRONAMINES;

ANIMALS; BIOLOGICAL TRANSPORT; FATTY ACIDS, NONESTERIFIED; GLUCOSE; HEP G2 CELLS; HEPATOCYTES; HUMANS; KETONE BODIES; LIVER; MALE; RATS; RATS, WISTAR; THYRONINES;

EID: 84897880549     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0311     Document Type: Article

References (37)

1. Agretti P, De Marco G, Russo L, Saba A, Raffaelli A, MarchiniM, Chiellini G, Grasso L, Pinchera A, Vitti P et al. 2011 3-Iodothyronamine metabolism and functional effects in FRTL5 thyroid cells. Journal of Molecular Endocrinology 47 23-32.
2. Alberti KGMM & Hockaday TDR 1972 Rapid blood ketone body estimation in the diagnosis of diabetic ketoacidosis. BMJ 2 565-568.
3. Bradford MM 1976 A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 248-254.
4. Braulke LJ, Klingenspor M, DeBarber A, Tobias SC, Grandy DK, Scanlan TS & Heldmaier G 2008 3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilisation. Journal of Comparative Physiology B 178 167-177.
5. Chiellini G, Frascarelli S, Ghelardoni S, Carnicelli V, Tobias SC, DeBarber A, Brogioni S, Ronca-Testoni S, Cerbai E, Grandy DK et al. 2007 Cardiac effects of 3-iodothyronamine: a new aminergic system modulating cardiac function. FASEB Journal 21 1597-1608.
6. Chiellini G, Erba P, Carnicelli V, Manfredi C, Frascarelli S, Ghelardoni S, Mariani G & Zucchi R 2012 Distribution of exogenous [125I]-3-iodothyronamine in mouse in vivo: relationship with trace amine-associated receptors. Journal of Endocrinology 213 223-230.
7. Cumero S, Fogolari F, Domenis R, Zucchi R, Mavelli I & Contessi S 2012 Mitochondrial F(0) F(1)-ATP synthase is a molecular target of 3-iodothyronamine, an endogenous metabolite of thyroid hormone. British Journal of Pharmacology 166 2331-2347.
8. Dhillo WS, Bewick GA, White NE, Gardiner JV, Thompson EL, Bataveljic A, Murphy KG, Roy D, Patel NA, Scutt JN et al. 2009 The thyroid hormone derivative 3-iodothyronamine increases food intake in rodents. Diabetes, Obesity and Metabolism 11 251-260.
9. Di Nunzio M, Valli V & Bordoni A 2011 Pro- and anti-oxidant effects of polyunsaturated fatty acid supplementation in HepG2 cells. Prostaglandins, Leukotrienes and Essential Fatty Acids 85 121-127.
10. Galli E, Marchini M, Saba A, Berti S, Tonacchera M, Vitti P, Scanlan TS, Iervasi G & Zucchi R 2012 Detection of 3-iodothyronamine in human patients: a preliminary study. Journal of Clinical Endocrinology and Metabolism 97 E69-E74.
11. Hackenmueller SA & Scanlan TS 2012 Identification and quantification of 3-iodothyronamine metabolites in mouse serum using liquid chromatography-tandem mass spectrometry. Journal of Chromatography 1256 89-97.
12. Hackenmueller SA, Marchini M, Saba A, Zucchi R & Scanlan TS 2012 Biosynthesis of 3-iodothyronamine (T1AM) is dependent on the sodium-iodide symporter and thyroperoxidase but does not involve extrathyroidal metabolism of T4. Endocrinology 153 5659-5667.
13. Hart ME, Suchland KL, Miyakawa M, Bunzow JR, Grandy DK & Scanlan TS 2006 Trace amine-associated receptor agonists: synthesis and evaluation of thyronamines and related analogues. Medicinal Chemistry 49 1101-1112.
14. Haviland JA, Reiland H, Butz DE, Tonelli M, Porter WP, Zucchi R, Scanlan TS, Chiellini G & Assadi-Porter FM 2013 NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T1 AM treatment. Obesity 21 2538-2544.
15. Hettinger BD, Schuff K, Marks D & Scanlan TS 2010 3-Iodothyronamine (T1AM) causes weight loss in mice via reduction in food consumption. 14th International Thyroid Congress, Paris, France. Abstract OC-141.
16. Hoefig CS, Köhrle J, Brabant G, Dixit K, Yap B, Strasburger CJ &Wu Z 2011 Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibodybased chemiluminescent serum immunoassay. Journal of Clinical Endocrinology and Metabolism 96 1864-1872.
17. Ianculescu AG, Giacomini KM & Scanlan TS 2009 Identification and characterization of 3-iodothyronamine intracellular transport. Endocrinology 150 1991-1999.
18. Jakobs TC, Mentrup B, Schmutzler C, Dreher I & Köhrle J 2002 Proinflammatory cytokines inhibit the expression and function of human type I 50-deiodinase in HepG2 hepatocarcinoma cells. European Journal of Endocrinology 146 559-566.
19. Klieverik LP, Janssen SF, van Riel A, Foppen E, Bisschop PH, Serlie MJ, Boelen A, Ackermans MT, Sauerwein HP, Fliers E et al. 2009 Thyroid hormone modulates glucose production via a sympathetic pathway from the hypothalamic paraventricular nucleus to the liver. PNAS 106 5966-5971.
20. Liggett SB 2004 The two-timing thyroid. Nature Medicine 10 582-583.
21. Manni ME, De Siena G, Saba A, Marchini M, Dicembrini I, Bigagli E, Cinci L, Lodovici M, Chiellini G, Zucchi R et al. 2012 3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice. British Journal of Pharmacology 166 650-658.
22. Manni ME, De Siena G, Saba A, Marchini M, Landucci E, Gerace E, Zazzeri M, Musilli C, Pellegrini-Giampietro D, Matucci R et al. 2013 Pharmacological effects of 3-iodothyronamine (T1AM) in mice include facilitation of memory acquisition and retention and reduction of pain threshold. British Journal of Pharmacology 168 354-362.
23. Mario EG, Leonardo ES, Bassoli BK, Cassolla P, Borba-Murad GR, Bazotte RB& de Souza HM 2009 Investigation of the acute effect of leptin on the inhibition of glycogen catabolism by insulin in rat liver perfused in situ. Pharmacological Reports 61 319-324.
24. Miyakawa M & Scanlan TS 2006 Synthesis of [125I]-,[2H]-, and [3H]-labelled 3-iodothyronamine (T1AM). Synthetic Communications 36 891.
25. Piehl S, Hoefig CS, Scanlan TS & Köhrle J 2011 Thyronamines - past, present, and future. Endocrine Reviews 2 64-80.
26. Regard JB, Kataoka H, Cano DA, Camerer E, Yin L, Zheng YW, Scanlan TS, HebrokM& Coughlin SR 2007 Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. Journal of Clinical Investigation 117 4034-4043.
27. Roy G, Placzek E & Scanlan TS 2012 ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation. Journal of Biological Chemistry 287 1790-1800.
28. Saba A, Chiellini G, Frascarelli S, Marchini M, Ghelardoni S, Raffaelli A, Tonacchera M, Vitti P, Scanlan TS & Zucchi R 2010 Tissue distribution and cardiac metabolism of 3-iodothyronamine. Endocrinology 151 5063-5073.
29. Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, Frascarelli S, Crossley DA, Bunzow JR, Ronca-Testoni S et al. 2004 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nature Medicine 10 638-642.
30. Snead AN, SantosMS, Seal RP, Miyakawa M, Edwards RH & Scanlan TS 2007 Thyronamines inhibit plasma membrane and vesicular monoamine transport. ACS Chemical Biology 2 390-398.
31. Venditti P, Napolitano G, Di Stefano L, Chiellini G, Zucchi R, Scanlan TS & Di Meo S 2011 Effects of the thyroid hormone derivatives 3-iodothyronamine and thyronamine on rat liver oxidative capacity. Molecular and Cellular Endocrinology 341 55-62.
32. Vilá-Brau A, De Sousa-Coelho AL, Mayordomo C, Haro D & Marrero PF 2011 Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line. Journal of Biological Chemistry 286 20423-20430.
33. Weatherman RV 2007 A triple play for thyroid hormone. ACS Chemical Biology 2 377-379.
34. Wood WJ, Geraci T, Nilsen A, DeBarber AE & Scanlan TS 2009 Iodothyronamines are oxidatively deaminated to iodothyroacetic acids in vivo. Chembiochem 10 361-365.
35. Yao HR, Liu J, Plumeri D, Cao YB, He T, Lin L, Li Y, Jiang YY, Li J & Shang J 2011 Lipotoxicity in HepG2 cells triggered by free fatty acids. American Journal of Translational Research 3 284-291.
36. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK et al. 2001 Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413 131-138.
37. Zucchi R, Chiellini G, Scanlan TS & Grandy DK 2006 Trace amineassociated receptors and their ligands. British Journal of Pharmacology 49 967-978.